Ruijian Medicine's iPSC-Derived Ophthalmic Cell Therapy NouvSight001 Receives FDA Orphan Drug Designation

36Kr learned that NouvSight001, a breakthrough ophthalmic product by Wuhan iRegene, has been granted Orphan Drug Designation (ODD) by the U.S. FDA. According to reports, this product is aimed at treating "a series of retinitis pigmentosa indications" and is the first universal ophthalmic cell therapy product derived from induced pluripotent stem cells (iPSC), developed by the iRegene team based on the company's unique "AI + chemical induction" platform.